메뉴 건너뛰기




Volumn 31, Issue 3, 2008, Pages 244-249

Lenalidomide therapy for metastatic renal cell carcinoma

Author keywords

Angiogenesis inhibitor; Immunomodulatory; Lenalidomide; Renal cell cancer

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

EID: 44949155606     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31815e451f     Document Type: Article
Times cited : (30)

References (25)
  • 2
    • 0036251451 scopus 로고    scopus 로고
    • Global increases in kidney cancer incidence, 1973-1992
    • Mathew A, Devesa SS, Fraumeni JF Jr, et al. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev. 2002;11:171-178.
    • (2002) Eur J Cancer Prev , vol.11 , pp. 171-178
    • Mathew, A.1    Devesa, S.S.2    Fraumeni Jr, J.F.3
  • 3
    • 28844484134 scopus 로고    scopus 로고
    • Medical progress: Renal-cell carcinoma
    • Cohen HT, McGovern FJ. Medical progress: renal-cell carcinoma. N Engl J Med. 2005;353:2477-2490.
    • (2005) N Engl J Med , vol.353 , pp. 2477-2490
    • Cohen, H.T.1    McGovern, F.J.2
  • 4
    • 0041691157 scopus 로고    scopus 로고
    • Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal Cancer
    • Stadler WM, Huo D, George C, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal Cancer. J Urol. 2003;170:1141-1145.
    • (2003) J Urol , vol.170 , pp. 1141-1145
    • Stadler, W.M.1    Huo, D.2    George, C.3
  • 5
    • 0034113335 scopus 로고    scopus 로고
    • Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma
    • Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:1928-1935.
    • (2000) J Clin Oncol , vol.18 , pp. 1928-1935
    • Motzer, R.J.1    Mazumdar, M.2    Bacik, J.3
  • 6
    • 0033847587 scopus 로고    scopus 로고
    • Long-term survival update for high-dose recombinant interleukin-2 patients with renal cell carcinoma
    • Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 patients with renal cell carcinoma. Cancer J Sci Am. 2000;1(Suppl 6):S55-S57.
    • (2000) Cancer J Sci Am , vol.1 , Issue.SUPPL. 6
    • Fisher, R.I.1    Rosenberg, S.A.2    Fyfe, G.3
  • 7
    • 0038016523 scopus 로고    scopus 로고
    • Thalidomide therapy for renal cell carcinoma
    • Amato RJ. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol. 2003;46:59-65.
    • (2003) Crit Rev Oncol Hematol , vol.46 , pp. 59-65
    • Amato, R.J.1
  • 8
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 9
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 10
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G, Carducci T, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356: 2271-2281.
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, T.2    Tomczak, P.3
  • 11
    • 33846821872 scopus 로고    scopus 로고
    • Targeted therapy for metastatic renal cell carcinoma
    • Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24:5601-5608.
    • (2006) J Clin Oncol , vol.24 , pp. 5601-5608
    • Motzer, R.J.1    Bukowski, R.M.2
  • 12
    • 0033532557 scopus 로고    scopus 로고
    • Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
    • Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production. Bioorg Med Chem Lett. 1999;9:1625-1630.
    • (1999) Bioorg Med Chem Lett , vol.9 , pp. 1625-1630
    • Muller, G.W.1    Chen, R.2    Huang, S.Y.3
  • 13
    • 0033168605 scopus 로고    scopus 로고
    • Differential cytokine mod- ulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α
    • Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine mod- ulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999;163: 380-386.
    • (1999) J Immunol , vol.163 , pp. 380-386
    • Corral, L.G.1    Haslett, P.A.J.2    Muller, G.W.3
  • 14
    • 20144375457 scopus 로고    scopus 로고
    • Orally administered lenalido-mide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
    • Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalido-mide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69: 56-63.
    • (2005) Microvasc Res , vol.69 , pp. 56-63
    • Dredge, K.1    Horsfall, R.2    Robinson, S.P.3
  • 15
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 16
    • 67650047103 scopus 로고    scopus 로고
    • National Cancer Institute: Common Terminology Criteria for Adverse Events NCI CTCAE, Version 3.0; 2006
    • National Cancer Institute: Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0; 2006.
  • 17
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevaci-zumab, an anti-vascular endothelial growth factory antibody, for metastatic renal Cancer
    • Yang JC, Haworth L, Sperry RV, et al. A randomized trial of bevaci-zumab, an anti-vascular endothelial growth factory antibody, for metastatic renal Cancer. N Engl J Med. 2003;349:427-434.
    • (2003) N Engl J Med , vol.349 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sperry, R.V.3
  • 18
    • 0036138580 scopus 로고    scopus 로고
    • Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    • Motzer R, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296.
    • (2002) J Clin Oncol , vol.20 , pp. 289-296
    • Motzer, R.1    Bacik, J.2    Murphy, B.A.3
  • 19
    • 33751565011 scopus 로고    scopus 로고
    • Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
    • Choueiri TK, Dreicer R, Rini BI, et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer. 2006;107:2609-2616.
    • (2006) Cancer , vol.107 , pp. 2609-2616
    • Choueiri, T.K.1    Dreicer, R.2    Rini, B.I.3
  • 20
    • 0035412366 scopus 로고    scopus 로고
    • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    • Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
    • (2001) Blood , vol.98 , pp. 210-216
    • Davies, F.E.1    Raje, N.2    Hideshima, T.3
  • 21
    • 0036839013 scopus 로고    scopus 로고
    • Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    • Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
    • (2002) Blood , vol.100 , pp. 3063-3067
    • Richardson, P.G.1    Schlossman, R.L.2    Weller, E.3
  • 22
    • 23844455555 scopus 로고    scopus 로고
    • Final findings from a phase II, placebo controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
    • Abstract 4544
    • Raitan MJ, Eisen T, Stadler WM, et al. Final findings from a phase II, placebo controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2005;23:388[Abstract 4544].
    • (2005) Proc Am Soc Clin Oncol , vol.23 , pp. 388
    • Raitan, M.J.1    Eisen, T.2    Stadler, W.M.3
  • 23
    • 33748614966 scopus 로고    scopus 로고
    • Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival
    • Abstract 4524
    • Eisen T, Bukowski RM, Staehler M, et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol. 2006;24:18S(Abstract 4524).
    • (2006) J Clin Oncol , vol.24
    • Eisen, T.1    Bukowski, R.M.2    Staehler, M.3
  • 25
    • 84869379519 scopus 로고    scopus 로고
    • Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (MRCC). J Clin Oncol, ASCO Annual Meeting Proceedings Part I. 2006;24(June 20 Supplement) (Abstract LBA3).
    • Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (MRCC). J Clin Oncol, ASCO Annual Meeting Proceedings Part I. 2006;24(June 20 Supplement) (Abstract LBA3).


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.